ArticleClinical kidney journal2026
Erythroferrone is associated with the hepcidin-to-ferritin ratio and cardiovascular mortality in chronic kidney disease.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of erythroferrone, a hormone synthesized in erythroid cells that suppresses hepatic production of hepcidin to increase systemic iron availability during erythropoiesis expansion, has not been sufficiently characterized in chronic kidney disease (CKD). Therefore, we evaluated its determinants and its association with mortality risk in patients with CKD stages 3-5. Methods: In this cross-sectional study with longitudinal follow-up, erythroferrone, hepcidin, ferritin, transferrin saturation (TSAT), C-reactive protein (CRP) and nutritional status were assessed in 377 CKD patients [92 patients with CKD stages 3-4, 210 non-dialysed patients with CKD stage 5 and 75 patients on peritoneal dialysis (PD)]. Regression analyses were performed to investigate the association between erythroferrone and relevant variables. The association between erythroferrone and mortality risk was analysed using Fine-Gray analysis, accounting for kidney transplantation as a competing risk. Results: Erythroferrone, hepcidin and ferritin were higher in PD patients and in CKD 5 patients as compared with CKD 3-4 patients, whereas the hepcidin-to-ferritin ratio did not differ between the cohorts. In linear regression analysis, erythroferrone was positively associated with the reticulocyte count, CRP and CKD severity and negatively associated with TSAT and the hepcidin-to-ferritin ratio (and hepcidin). Further adjustment for erythropoiesis-stimulating agents (ESAs) revealed that erythroferrone no longer showed an association with the severity of CKD or CRP levels. Finally, erythroferrone was linked to both all-cause mortality and cardiovascular mortality. Conclusions: Erythroferrone in CKD patients associated with the reticulocyte count and ESA dose and was inversely correlated with the hepcidin-to-ferritin ratio and TSAT, while its relationship with CKD stage may reflect ESA therapy. Higher circulating erythroferrone levels are associated with an increased mortality risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.